Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 4.3%

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) traded up 4.3% on Wednesday . The company traded as high as $118.46 and last traded at $116.81. 2,968 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 963,238 shares. The stock had previously closed at $111.98.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of analyst reports. Credit Suisse Group upped their price target on Sarepta Therapeutics from $93.00 to $101.00 and gave the stock a “neutral” rating in a research report on Thursday, November 3rd. The Goldman Sachs Group increased their price target on Sarepta Therapeutics from $152.00 to $171.00 and gave the company a “buy” rating in a research note on Thursday, November 3rd. Oppenheimer increased their price target on Sarepta Therapeutics from $125.00 to $150.00 in a research note on Wednesday, August 3rd. Morgan Stanley increased their price target on Sarepta Therapeutics from $135.00 to $141.00 and gave the company an “equal weight” rating in a research note on Thursday, October 13th. Finally, Needham & Company LLC dropped their price target on Sarepta Therapeutics from $162.00 to $158.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $143.91.

Sarepta Therapeutics Price Performance

The stock has a fifty day moving average price of $110.70 and a 200-day moving average price of $95.00. The firm has a market capitalization of $10.07 billion, a PE ratio of -13.98 and a beta of 1.09. The company has a debt-to-equity ratio of 3.58, a quick ratio of 3.99 and a current ratio of 4.36.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($1.73). Sarepta Therapeutics had a negative net margin of 81.76% and a negative return on equity of 97.37%. The company had revenue of $230.30 million during the quarter, compared to analysts’ expectations of $234.55 million. During the same quarter in the prior year, the business posted ($0.60) earnings per share. The company’s revenue was up 21.6% compared to the same quarter last year. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post -8.17 EPS for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 57,100 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were purchased at an average cost of $104.43 per share, for a total transaction of $5,962,953.00. Following the purchase, the director now directly owns 108,178 shares in the company, valued at $11,297,028.54. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Michael Andrew Chambers purchased 57,100 shares of the stock in a transaction on Wednesday, September 14th. The stock was bought at an average price of $104.43 per share, with a total value of $5,962,953.00. Following the transaction, the director now owns 108,178 shares in the company, valued at approximately $11,297,028.54. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen Mayo sold 858 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $109.92, for a total value of $94,311.36. Following the sale, the director now directly owns 6,387 shares of the company’s stock, valued at approximately $702,059.04. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Utah Retirement Systems increased its stake in Sarepta Therapeutics by 0.7% in the 3rd quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company’s stock valued at $1,654,000 after buying an additional 100 shares during the period. Neuberger Berman Group LLC lifted its stake in Sarepta Therapeutics by 2.5% in the third quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 105 shares in the last quarter. Captrust Financial Advisors increased its holdings in Sarepta Therapeutics by 3.1% during the second quarter. Captrust Financial Advisors now owns 3,534 shares of the biotechnology company’s stock worth $265,000 after buying an additional 107 shares during the last quarter. Benchmark Investment Advisors LLC boosted its position in shares of Sarepta Therapeutics by 2.9% in the third quarter. Benchmark Investment Advisors LLC now owns 3,883 shares of the biotechnology company’s stock valued at $429,000 after acquiring an additional 110 shares during the period. Finally, Brinker Capital Investments LLC lifted its holdings in shares of Sarepta Therapeutics by 3.6% in the third quarter. Brinker Capital Investments LLC now owns 4,297 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 150 shares during the last quarter. 82.18% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Read More

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.